Spruce's successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug

Spruce Biosciences advanced towards FDA approval of its tralesinidase alfa enzyme replacement therapy for Sanfilippo syndrome type B with positive regulatory meetings and completed manufacturing tasks enabling a planned Q4 2026 filing.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.